Fosfomycin 6000 MG Injection — RxCUI 2725577
RxNorm drug concept · Semantic clinical drug
RxCUI 2725577
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2725577
Official nameFosfomycin 6000 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asfosfomycin 6 GM Injection
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Fosfomycin: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- That depends on the type of infection and which form of fosfomycin you're being prescribed. The oral powder or solution (brands like Monurol or Fosfomycin Tromethamine) is a single...
- What kind of UTI is fosfomycin used for — and is it right for me?
- You pour the entire contents of the single sachet into about half a cup (3–4 ounces) of cool water, stir until it dissolves completely, and drink it right away. Don't use hot water...
- How do I take the oral powder — do I need water or food?
🕸️ Concept Web — How Fosfomycin 6000 MG Injection Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Fosfomycin 6000 MG Injection
RxCUI 2725577 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Fosfomycin
4550IN
-
Fosfomycin
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Contepo
2725578BN
-
Contepo
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Fosfomycin Injection
2725576SCDF -
Fosfomycin Injectable Product
1162074SCDG -
Fosfomycin Injection [Contepo]
2725581SBDF -
Contepo Injectable Product
2725580SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Fosfomycin Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Fosfomycin 6000 MG
2725575SCDC -
Fosfomycin 6000 MG Injection [Contepo]
2725582SBD -
Fosfomycin 6000 MG [Contepo]
2725579SBDC
-
Fosfomycin 6000 MG
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Fosfomycin 6000 MG
SCDC · 2725575 -
Fosfomycin Injection
SCDF · 2725576 -
Fosfomycin Injectable Product
SCDG · 1162074
Brand-Name Concepts
-
Fosfomycin 6000 MG Injection [Contepo]
SBD · 2725582 -
Fosfomycin 6000 MG [Contepo]
SBDC · 2725579 -
Fosfomycin Injection [Contepo]
SBDF · 2725581 -
Contepo Injectable Product
SBDG · 2725580 -
Contepo
BN · 2725578
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2725577 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 71288-0035-52 | 12 VIAL, GLASS in 1 CARTON (71288-035-52) / 1 INJECTION, PO... | Contepo | Meitheal Pharmaceuticals Inc. | 2025-10-22 |
Observed labelers:
Meitheal Pharmaceuticals Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.